Current treatments for RA are divided into conventional disease-modifying anti-rheumatic drugs (csDMARDs), such as methotrexate, or biological DMARDs (bDMARDs), such as tumor necrosis factor-alpha (TNFα) inhibitors (infliximab, adalimumab, or etanercept), costimulation modifiers (abatacept), interleukin-6 inhibitors (tocilizumab), and B cell-depleting drugs (rituximab) (2) or target synthetic DMARDs (tsDMARDs), such as Janus kinase (JAK) inhibitors (3). This evidence concerns the gene IL6 and rheumatoid arthritis.